cb1-in-1

CB1-IN-1 (DBPR211) 是新型的外周大麻素-1受体 (CB1R) 拮抗剂，作用于CB1R (EC50 = 3 nM) 和 CB2R 的Ki 分别为0.3 nM 和 21 nM。

ABCB1-IN-1 (compound 3) 为高效ABCB1抑制剂，可诱导细胞凋亡。含1-苯甲基咪唑基团，其对Colo205与Colo320细胞系展现出的IC50分别为1.26 μM与2.21 μM。

PSNCBAM-1 (PSNCBAM 1) 是一种 CB1 受体负变构调节剂 (EC50 = 0.1 μM)，在体内具有吞噬作用。 PSNCBAM-1 可用于肥胖研究。

Arvanil (N-Vanillylarachidonamide) 是一种合成辣椒素-安非他命杂交体，也是香草素受体1 (VR1) 和大麻素 1 (CB1)的配体，具有神经保护活性，抑制痉挛，通过在体内诱导 HCC 细胞铁死亡来增强顺铂化疗敏感性，通过与 MICU1 结合诱导肝细胞癌的铁死亡。

Rimonabant (SR141716) 是一种选择性的、能透过血脑屏障的中心大麻素受体 1 拮抗剂， Ki 值为 1.8 nM。它也能够抑制分枝杆菌膜蛋白 3。

COR659 是一种有效的 GABAB 的阳性变构调节剂。COR659具有缓解大鼠对酒精和巧克力成瘾的作用。

RTICBM-189 是可透过血脑屏障的大麻素 1 型受体变构调节剂，在 Ca2+动员试验中pIC50为 7.54，对 hCB1和 mCB1的 pIC50分别为 5.29 和 6.25。

AM9405是一种新型的外周活性大麻素1型 (CB1)和5-羟色胺3型受体激动剂。 AM9405抑制回肠和结肠的抽搐收缩，IC50分别为45.71 和 0.076 nM。AM9405 在生理条件下显着减缓小鼠肠道蠕动.

CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.

Leelamine hydrochloride, a tricyclic diterpene extracted from pine tree bark, inhibits the transcriptional activity of the androgen receptor, known to regulate fatty acid synthesis [2,3]. This compound acts as a cannabinoid receptor type 1 (CB1) agonist and suppresses SREBP1-regulated fatty acid lipid synthesis in prostate cancer cells, irrespective of androgen receptor status.

Taranabant (MK-0364) 是一种具有选择性和高效性的 cannabinoid 1 (CB1) 受体反向激动剂，可用于研究肥胖和尼古丁依赖。

CB1 antagonist 2 (AM4113) 是一种 caimabinoid 1 拮抗剂，在体内抑制 CB1 的IC50值为 25.5 nM。

Compound 5.3 (CB1 2 receptor-1)为CB1 2受体激动剂，常用于血管生成领域的研究。

Delta8-THC acetate (Delta8-tetrahydrocannabinol) 是一种精神活性的大麻素，能够结合至大麻素受体 1 (CB1 receptor)，并展现抗恶心、食欲刺激及抗炎的特性。它可能具有神经保护作用，可在抗焦虑和抗抑郁的研究中应用。

LH-21 是一种有效的体内中性大麻素 CB1受体拮抗剂。LH-21 会导致剂量依赖性进食抑制，减少肥胖 Zucker 大鼠的食物摄入和体重增加。

Ibipinabant (SLV319) 是一种有效，选择性和具有口服活性的大麻素 CB1 受体 (cannabinoid CB1 receptor) 的拮抗剂，Ki 值为 7.8 nM。Ibipinabant 对 CB1 的选择性超过 CB2 (Ki=7943 nM) 的 1000 倍以上。Ibipinabant 可用于肥胖和糖尿病的研究。

AM6545 是一种具有选择性和高效性的外周限制性大麻素受体 1 （CB1）拮抗剂，抑制 CB2 受体，可改善低代谢性肥胖并改善谷氨酸钠诱导的肥胖小鼠的脂肪因子分泌，可用于研究肥胖症和糖尿病。

O-2050 是一种高亲和力的大麻素CB1受体拮抗剂，Ki 为 2.5 nM。O-2050 抑制大麻素 CB2受体，Ki 为 0.2 nM。O-2050 减少了小鼠的食物摄入量，并且引起小鼠运动。

LEI-101 是有效的、选择性的、具有口服活性的大麻素CB2受体激动剂。LEI-101对 hCB2 的 pEC50值为 8，对 hERG 的 pKi 值小于 4。LEI-101 与 CB2 受体的结合能力比 CB1 强100 倍。LEI-101 具有炎症及氧化应激相关疾病的治疗潜力。

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position. O-7460 is a selective inhibitor of 2-AG biosynthesis via DAGLα (IC50 = 690 nM). It demonstrates much weaker inhibition towards human monoacylglycerol lipase and rat brain fatty acid amide hydrolase (IC50s > 10 μM) and does not bind to CB1 or CB2 cannabinoid receptors (Kis > 10 μM). At 0-12 mg kg, i.p. in mice, O-7460 was reported to dose-dependently inhibit high-fat diet intake and reduce body weight.

ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM). It inhibits food consumption in nonfasted mice without affecting motor activity. ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.

URB754 is a potent and noncompetitive inhibitor of monoacylglycerol lipase (MAGL), exhibiting an IC50 value of 200 nM for the recombinant rat brain enzyme. However, it does not inhibit human recombinant, rat brain, or mouse brain MAGL at concentrations up to 100 μM. There is evidence that the MAGL inhibitory activity of URB754 may be attributed to the impurity bis(methylthio)mercurane (IC50 = 11.9 nM for rat recombinant MAGL) that is found in commercial preparations. URB754 inhibits rat brain fatty acyl amide hydrolase (FAAH) with an IC50 value of 32 μM and binds weakly to the rat central cannabinoid (CB1) receptor with an IC50 value of 3.8 μM. It does not inhibit COX-1 or COX-2 at concentrations up to 100 μM. Inhibition of MAGL hydrolysis of 2-arachidonoyl glycerol (2-AG) is associated with enhanced stress-induced analgesia and may represent a novel drug target in pain and stress management.

N-Acylated ethanolamines (NAE) are naturally-occurring lipids that have diverse bioactivities. For example, arachidonoyl ethanolamide (AEA) is an endogenous neurotransmitter that evokes cellular responses by activating the cannabinoid receptors, central cannabinoid (CB1) and peripheral cannabinoid (CB2). The different types of NAE are derived from glycerophospho-linked precursors by the activity of glycerophosphodiesterase 1 (GDE1). Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is the metabolic precursor of palmitoyl ethanolamide (PEA). PEA is an endogenous cannabinoid found in brain, liver, and other mammalian tissues, that has potent anti-inflammatory activity in vivo. PEA has low affinity for peripheral cannabinoid (CB2) and no appreciable affinity for central cannabinoid (CB1), suggesting that its efficacy is through a different receptor.

Arachidonoyl 2-chloroethylamide (ACEA) is a potent and selective cannabinoid (CB) receptor 1 agonist with Ki values of 1.4 and >2,000 nM for CB1 and CB2 receptors, respectively. In whole animal experiments, ACEA induces hypothermia in mice with the same efficacy as arachidonoyl ethanolamide , in spite of its higher affinity for the CB1 receptor. These data have been interpreted to indicate that ACEA may be a substrate for fatty acid amide hydrolase (FAAH), and thus only transiently available in whole animal experiments.